Reworked Deal With Ipsen Gives GTx Extended Runway To Get Toremifene To Finish Line
This article was originally published in The Pink Sheet Daily
Executive Summary
GTx needs to run a second Phase III trial of the prostate cancer drug due to a "complete response" letter from FDA.